Impact of Prolonged SARS-CoV-2 Dosing Interval in Hemodialysis Patients

Kidney Int Rep. 2024 Jun 24;9(8):2575-2577. doi: 10.1016/j.ekir.2024.04.072. eCollection 2024 Aug.

Caroline Lamarche^{1

2}, Karthik Tennankore³, Lorie Marchitto^{4

5}, William Beabien-Souligny^{2

4}, Rémi Goupil^{2

6}, Annie-Claire Nadeau-Fredette^{1

2}, Lakshman Gunaratnam⁷, Fabrice Mac-Way⁸, Mehdi Benlarbi⁴, Debashree Chatterjee⁴, Alexander Tom⁹, Halima Medjahed⁴, Daniel E Kaufmann^{4

5}, Andrés Finzi^{4

5

10}, Rita S Suri^{9

11}; Réseau Néphrologique Québécois (Quebec Renal Network) COVID-19 Study Investigators

¹ Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada.
² Département de Médecine, Université de Montréal, Montréal, Quebec, Canada.
³ Department of Medicine, Dalhousie University, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada.
⁴ Centre de Recherche du CHUM, Montréal, Quebec, Canada.
⁵ Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Quebec, Canada.
⁶ Centre de recherche de l'Hôpital du Sacré-Cœur de Montréal, Montréal, Quebec, Canada.
⁷ Division of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
⁸ Centre de recherche du CHU de Québec, Hôtel-Dieu de Québec and Division of Nephrology, Faculty and Department of Medicine, Université Laval, Quebec, Canada.
⁹ Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
¹⁰ Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
¹¹ Division of Nephrology, Department of Medicine, McGill University, Montreal, Quebec, Canada.

No abstract available